Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

The therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...